GFM
SYRE icon

GF Fund Management’s Spyre Therapeutics SYRE Stock Holding History

GF Fund Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Sell
1,664
-79
-5% -$5.76K ﹤0.01% 298
2026
Q1 		$87.9K Buy
1,743
+220
+14% +$8.29K ﹤0.01% 350
2025
Q4 		$49.9K Buy
1,523
+224
+17% +$5.85K ﹤0.01% 406
2025
Q3 		$21.8K Sell
1,299
-203
-14% -$3.31K ﹤0.01% 479
2025
Q2 		$22.5K Hold
1,502
– – ﹤0.01% 490
2025
Q1 		$24.2K Buy
1,502
+270
+22% +$5.62K ﹤0.01% 483
2024
Q4 		$28.7K Buy
+1,232
New +$36.1K ﹤0.01% 436

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

GF Fund Management's SYRE Position: Q2 2026 in Review

GF Fund Management reduced its Spyre Therapeutics (SYRE) stake by 4.5% in Q2 2026, selling an estimated $5.76K and leaving 1,664 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

GF Fund Management first reported a position in SYRE in Q4 2024 and has held it in 7 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • GF Fund Management held 1,664 shares of Spyre Therapeutics worth $148K as of Q2 2026.
  • GF Fund Management sold 79 Spyre Therapeutics shares in Q2 2026, an estimated $5.76K.
  • Spyre Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #298 holding.
  • GF Fund Management first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.